Document resource
Introduction High frequency bronchoscopic microwave ablation (MWA) is a novel alternative to conventional lung cancer treatments.Aims To investigate the feasibility of high frequency bronchoscopic MWA in patients with lung cancer.Methods We report the interim results of a single arm prospective study enrolling subjects with confirmed malignant or highly suspicious pulmonary nodules ≤20 mm, who are not surgical candidates.Results 19 nodules were ablated in 19 subjects. Median age was 73 years. 68.4% were female. 58% of subjects had previous thoracic surgery, radiotherapy, or percutaneous ablation. 17 out of 19 high frequency MWA were delivered robotically.58% of the nodules were solid; 42% were part-solid. Median baseline long axis nodule length was 9.9 mm. Median distance was 15.1 mm from pleura and 43.1 mm from central zone. Median procedure time was 60 mins, with a median hospital stay length of 1 day.Median length of ablation zone was 27.1 mm at Day1 (n=19), 21.6 mm at 1-month (n=16), 17.1 mm at 3-month (n=15), 16.2 mm at 6-month (n=12) and 14.5 mm at 12-month (n=6).Median patient-reported outcomes are as follows (*p<0.05,**p<0.001 compared to baseline):Abstract P218 Table 1 Time post-ablation Baseline (n=19) Day 1 (n=19) Month 1 (n=16) Month 3 (n=15) EQ-5D Index (IQR) 0.8 (0.2) 1.0 (0.2)** 0.8 (0.3) 0.8 (0.2) EQ-VAS Score (IQR) 70 (25) 80 (20)* 80 (17.5) 80 (25) Pain score (IQR) 0 (3.0) 0 (1.0) 0 (2.0) 0 (0) Disease progression occurred in 1 patient at 6 months, and 1 at 12 months.Conclusion Interim data suggests high frequency bronchoscopic MWA may be a feasible alternative for treating patients with lung cancer who are not suitable for surgery, and is associated with low morbidity.